Table 1 NIRS variables at end point between placebo and loratadine during +Gz exposure with GOR and ROR.
From: A new evaluation method for +Gz tolerance with loratadine by using a near-infrared spectroscopy
GOR | ROR | |||||
|---|---|---|---|---|---|---|
NIRS Variable | Relaxed | Straining | Straining | |||
Placebo | Loratadine | Placebo | Loratadine | Placebo | Loratadine | |
ΔO 2 Hb (μmol·L -1 ) | -10.5 ± 5.6 | -11.1 ± 5.7 | -17.4 ± 8.1 | -16.9 ± 7.4 | -14.7 ± 7.2 | -15.0 ± 6.4 |
ΔHHb (μmol·L -1 ) | 0.5 ± 2.4 | -0.1 ± 3.4 | 2.8 ± 1.2 | 1.4 ± 4.6 | 0.7 ± 3.0 | 1.9 ± 3.7 |
ΔcHb (μmol·L -1 ) | -11.3 ± 6.8 | -12.8 ± 8.6 | -13.2 ± 6.8 | -15.5 ± 12.6 | -13.6 ± 7.0 | -12.0 ± 7.6 |
TOI% | 67.6 ± 4.5 | 70.2 ± 6.4 | 64.8 ± 3.7 | 67.2 ± 6.9 | 63.5 ± 4.8 | 66.3 ± 5.7 |
Baseline | 72.4 ± 4.7 | 73.6 ± 5.1 | 72.2 ± 4.9 | 73.7 ± 4.7 | ||
ΔTOI% | -4.8 ± 2.5 | -3.3 ± 3.2 | -7.6 ± 2.2 | -6.4 ± 4.0 | -8.8 ± 1.5 | -7.4 ± 3.1 |